Pablo Corral/LinkedIn
Oct 29, 2025, 07:39
Pablo Corral: Pushing the Limits of LDLc: Emerging Paradigms in CV Risk Reduction
Pablo Corral, Past President of Argentine Lipid Society, has shared a post on LinkedIn:
“Pushing the limits of LDLc: Emerging paradigms in CV risk reduction
- Modern guidelines now target LDL-C <55 mg/dL, and even <40 mg/dL for the highest-risk patients.
- Evidence from FOURIER, ODYSSEY, and IMPROVE-IT confirms that the lower, the better — with no safety concerns, even below 25 mg/dL.
- Genetic data (PCSK9 LoF, APOB, ANGPTL3) reinforce that lifelong low LDL-C protects against ASCVD.
- Emerging therapies — PCSK9 inhibitors, inclisiran, bempedoic acid, ANGPTL3 inhibitors — make these targets achievable.
- Cognitive, endocrine, and hemorrhagic risks remain none at very low LDL-C.
The real challenge is no longer how low can we go, but how many actually get there.”
Stay updated with Hemostasis Today.
-
Jun 26, 2026, 04:42Jonathan James: Amplifying Voices Across the Bleeding Disorders Community
-
Jun 26, 2026, 04:02Rick Kapur: Advancing Hematology Through Global Collaboration at EHA 2026 and ISBT
-
Jun 26, 2026, 02:06Giovanni Merlino: Scientific Progress in Secondary Stroke Prevention at Udine Stroke Congress 2026
-
Jun 26, 2026, 01:48Michael Stark: Highlights from ISBT 2026 on RBC Transfusion and NEC in Neonates
-
Jun 25, 2026, 23:08Geert Verheyden: Belgium’s Vision for Better Stroke Care Across the Continuum
-
Jun 25, 2026, 21:04Else Charlotte Sandset: Pleasure to Welcome Polish Delegation to Oslo University Hospital Stroke Tour
-
Jun 25, 2026, 19:32Javier M. Floren: A Blood Clot Is One of the Most Impressive Examples of Teamwork You’ll Ever See
-
Jun 25, 2026, 19:31Marcin Krzysztof Maniak: Linking Tissue Mechanics to Inflammation in Health and Disease
-
Jun 25, 2026, 19:29Deepak Rawat: A Diagnosis Like Immune Thrombocytopenia Changes Your Perspective